Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges

Psychopharmacology

Volumn 143, Issue 4, 1999, Pages 408-416

  Apelqvist, Gustav ^a   Wikell, Cecilia ^a   Hindfelt, Bengt ^a   Bergqvist, Peter B F ^a   Andersson, Gunnar ^b   Bengtsson, Finn ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia Oncology Immunology   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antidepressants; Behavior; Citalopram; Hepatic encephalopathy (HE); Portacaval shunt (PCS); Venlafaxine

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEPATIC ENCEPHALOPATHY; INFORMATION PROCESSING; LOCOMOTION; MALE; NONHUMAN; PORTOCAVAL SHUNT; PRIORITY JOURNAL; RAT; REARING; SEROTONIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION; SYNDROME DELINEATION; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; CHRONIC DISEASE; CITALOPRAM; CYCLOHEXANOLS; HEPATIC ENCEPHALOPATHY; LOCOMOTION; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0032901160     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050966     Document Type: Article

References (65)

1. Adams RD, Foley JM (1953) The neurological disorder associated with liver disease. In: Merritt HH, Hare CC (eds) Metabolic and toxic disease of the nervous system. Williams & Wilkins, Baltimore, pp 198-237
2. 1A receptor agonists flesinoxan and 8-OH-DPAT in the rat. Eur J Pharmacol 200:259-266
3. Albinsson A, Andersson G, Andersson K, Vega-Matuszcyk J, Larsson K (1996) The effects of lesion in the mesencephalic raphe systems on male rat sexual behavior and locomotor activity. Behav Brain Res 80:57-63
4. Apelqvist G, Hindfelt B, Andersson G, Bengtsson F (1997) Central versus peripheral spontaneous behavioral abnormalities in experimental hepatic encephalopathy. Physiol Behav 61: 851-856
5. Apelqvist G, Hindfelt B, Andersson G, Bengtsson F (1998) Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field. Behav Brain Res 93:25-32
6. Bengtsson F (1987) Chronic portal-systemic encephalopathy. An experimental study with special reference to brain serotonin. Thesis Bulletin No. 66, Department of Surgery, Lund University, Lund, Sweden, pp 1-90
7. Bengtsson F (1992) Neurotransmission failure in hepatic encephalopathy involving the combined action of different brain tryptophan-ralated pathology: a speculative synthesis. In: Ishiguro I, Kido R, Nagatsu T, Nagamura Y, Ohta Y (eds) Advances in tryptophan research. Fujita Health University Press, Toyoake, Japan, pp 303-308
8. Bengtsson F, Gage FH, Jeppsson B, Nobin A, Rosengren E (1985) Brain monoamine metabolism and behavior in portacaval-shunted rats. Exp Neurol 90:21-35
9. Bengtsson F, Nobin A, Falck B, Gage FH, Jeppsson B (1986) Portacaval shunt in the rat: selective alterations in behavior and brain serotonin. Pharmacol Biochem Behav 24:1611-1616
10. Bengtsson F, Bugge M, Brun A, Falck B, Henriksson KG, Nobin A (1988) The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology. J Neurol Sci 83:109-122
11. Bengtsson F, Bergqvist PBF, Apelqvist G (1997) Brain tryptophan perturbations in hepatic encephalopathy: implications for effects by neuropsychiatric drugs in clinical practice. Adv Exp Med Biol 420:1-33
12. Bergeron M, Reader TA, Pomier Layrargues G, Butterworth RF (1989) Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 14:853-859
13. Bergeron M, Swain MS, Reader TA, Grondin L, Butterworth RF (1990) Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval shunted rat. J Neurochem 55:222-229
14. Bergqvist PBF, Vogels BAPM, Bosman DK, Maas MAW, Hjorth S, Chamuleau RAFM, Bengtsson F (1995) Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. J Neurochem 64:1238-1244
15. Bergqvist PBF, Hjorth S, Audet RM, Apelqvist G, Bengtsson F, Butterworth RF (1996) Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo. Eur Neuropsychopharmacol 6:317-324
16. Bergqvist PBF, Hjorth S, Apelqvist G, Bengtsson F (1997a) Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. Metab Brain Dis 12:193-202
17. Bergqvist PBF, Hjorth S, Wikell C, Apelqvist G, Bengtsson F (1997b) p-Chloroamphetamine-and d-fenfluramine induced brain serotonin release in experimental portal-systemic encephalopathy. Metab Brain Dis 12:229-236
18. Bergqvist PBF, Wikell C, Hjorth S, Apelqvist G, Bengtsson F (1997c) Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. Clin Neuropharmacol 20:511-522
19. Borg J, Warter JM, Schlienger JL, Imler M, Marescaux C, Mack G (1982) Neurotransmitter modifications in human cerebrospinal ßuid and serum during hepatic encephalopathy. J Neurol Sci 57:343-356
20. Conn HO, Lieberthal MM (1979) The hepatic coma syndromes and lactulose. Williams & Wilkins, Baltimore
21. Dalhoff K, Almdal TP, Bjerrum K, Keiding S, Mengel H, Lund J (1991) Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 41:351-354
22. DeVane CL (1994) Pharmacokinetics of newer antidepressants: clinical relevance. Am J Med 97:13S-23S
23. DeVane CL, Laizure SC, Sterwart JT, Kolts BE, Ryerson EG, Miller RL, Lai AA (1990) Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 10:328-332
24. Elsass P, Lund Y, Ranek L (1978) Encephalopathy in patients with cirrhosis of the liver. A neuropsychological study. Scand J Gastroenterol 13:241-247
25. Ferry N, Bernard N, Cuisinaud G, Rougier P, Trepo C, Sassard J (1994) Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundam Clin Pharmacol 8:463-473
26. Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience 84:413-429
27. Hale AS (1993) New antidepressants: use in high-risk patients. J Clin Psychol 54:61-70
28. 2 receptor agonist MK-212 reduces food intake and increases resting but prevents the behavioural satiety sequence. Pharmacol Biochem Behav 56:41-46
29. Hervás I, Bel N, Fernández AG, Palacios JM, Artigas F (1998) In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn-Schmiedeberg's Arch Pharmacol 358:315-322
30. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 260:251-255
31. 1A receptors or fl-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. Eur J Pharmachol 316:43-47
32. Holliday SM, Benfield P (1995) Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294
33. Holm E, Uhl W, Stamm S (1986) Safety of fluvoxamine for patients with chronic liver disease: biochemical variables, psychometric performance and EEG. Adv Pharmacother 2:151-165
34. Holm E, Jacob S, Kortsik C, Leweling H, Fischer B (1988) Failure of selective serotonin re-uptake inhibition to worsen the mental state of patients with subclinical hepatic encephalopathy. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E (eds) Advances in ammonia metabolism and hepatic encephalopathy. Elsevier, Amsterdam, pp 474-486
35. Howell SR, Hicks DR, Scatina JA, Sisenwine SF (1994) Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24:315-327
36. Hyttel J, Arnt J, Sánchez C (1995) The pharmacology of citalopram. Rev Contemp Pharmacother 6:271-285
37. Invernizzi R, Belli S, Samanin R (1992) Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584:322-324
38. Jones EA, Gammal SH (1988) Hepatic encephalopathy. In: Arias WB, Jakoby WB, Popper H (eds) The liver biology and pathobiology. Raven Press, New York, pp 985-1005
39. 1A receptors. Naunyn-Schmiedeberg's Arch Pharmacol 352:583-584
40. 1C receptors. Br J Pharmacol 94:137-147
41. Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf H-D, Wolf D (1989) The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr Scand 80:91-92
42. Lee SH, Fisher B (1961) Portocaval shunt in the rat. Surgery 50:668-672
43. Mans AM, Hawkins RA (1986) Brain monoamines after portacaval anastomosis. Metab Brain Dis 1:45-52
44. Martin JR, Baettig K, Bircher J (1980) Maze patrolling, open-field behavior and runway activity following experimental portacaval anastomosis in rats. Physiol Behav 25:713-719
45. Martin JR, Oettinger R, Bättig K (1986) Behavioral effects of experimental portacaval anastomosis measured in dashiell and radial tunnel maze configurations. Physiol Behav 38:21-24
46. Milne RJ, Goa KL (1991) Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41:450-477
47. Mousseau DD, Butterworth RF (1994) Current theories on the pathogenesis of hepatic encephalopathy. Exp Biol Med 206:329-344
48. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivate. Biochem Pharmacol 35:4493-4497
49. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991) Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antide-pressant venlafaxine. Drug Dev Res 23:191-199
50. Möller H-J, Volz H-P (1996) Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 52:625-638
51. Orlando R, Benvenuti C, Mazzo M, Palatini P (1995) The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis. Br J Clin Pharmacol 39:445-448
52. Rehnström S, Siemert G, Hansson G, Vang J (1977) Chronic hepatic encephalopathy. A psychometrical study. Scand J Gastroenterol 12:305-311
53. Ribeiro J, Nordlinger F, Cynober L, Coudray-Lucas C, Baudrimont M, Legendre C, Delero R, Panis Y (1992) Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in portacaval-shunted rats. Hepatology 15:12-18
54. Rikkers L, Jenko P, Rudman D, Freides D (1978) Subclinical hepatic encephalopathy: detection, prevalence and relationship to nitrogen metabolism. Gastroenterology 75:462-469
55. Rössle M, Luft M, Herz R, Klein B, Lehmann M, Gerok W (1984) Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: serial analysis in plasma and cerebrospinal fluid during treatment with an adapted amino acid solution. Klin Wochenschr 62:867-875
56. Royer RJ, Royer-Morrot MJ, Paille F, Brraucand D, Schmitt J, Defrance R, Salvadori C (1989) Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis. Clin Pharmacokinet 16:186-191
57. Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dölle W (1981) Latent portasystemic encephalopathy I. Nature of cerebral function defects and their effect on fitness to drive. Dig Dis Sci 26:622-630
58. Schröder R, Müller O, Bircher J (1985) The portacaval and splenocaval shunt in the normal rat. A morphometric and functional reevaluation. J Hepatol 1:107-123
59. Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R (1994) Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14:322-329
60. 1D receptors in the modulation of prepulse inhibition of startle. Psychopharmacology 125:231-237
61. Stoeckel K, Pfefen JP, Mayersohn M, Schoerlin MP, Andressen C, Ohnhaus EE, Frey F, Guentert TW (1990) Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidey function. Acta Psychiatr Scand 360:94-97
62. Tarter RE, Hegedus AM, Van Thiel DH (1984) Neuropsychiatric sequelae of portal-systemic encephalopathy: a review. Int J Neurosci 24:203-216
63. Tricklebank MD, Smart JL, Bloxam DL, Curzon G (1978) Effects of chronic experimental liver dysfunction and L-tryptophan on behavior in the rat. Pharmacol Biochem Behav 9:181-189
64. Tricklebank MD, Bloxam DL, Kantamaneni BD, Curzon G (1981) Brain 5-hydroxytryptamine metabolism after portacaval anastomosis: relationship with ambulation. Pharmacol Biochem Behav 14:259-262
65. Wikell C, Bergqvist PBF, Hjorth S, Apelqvist G, Björk H, Bengtsson F (1998) Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy. Clin Neuropharmacol 21:296-306